183 related articles for article (PubMed ID: 19364823)
1. Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling.
Robertson SA; Koleva RI; Argetsinger LS; Carter-Su C; Marto JA; Feener EP; Myers MG
Mol Cell Biol; 2009 Jun; 29(12):3367-78. PubMed ID: 19364823
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling.
Feener EP; Rosario F; Dunn SL; Stancheva Z; Myers MG
Mol Cell Biol; 2004 Jun; 24(11):4968-78. PubMed ID: 15143188
[TBL] [Abstract][Full Text] [Related]
3. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.
Ungureanu D; Wu J; Pekkala T; Niranjan Y; Young C; Jensen ON; Xu CF; Neubert TA; Skoda RC; Hubbard SR; Silvennoinen O
Nat Struct Mol Biol; 2011 Aug; 18(9):971-6. PubMed ID: 21841788
[TBL] [Abstract][Full Text] [Related]
4. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
5. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.
Saharinen P; Silvennoinen O
J Biol Chem; 2002 Dec; 277(49):47954-63. PubMed ID: 12351625
[TBL] [Abstract][Full Text] [Related]
6. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
7. Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity.
Argetsinger LS; Stuckey JA; Robertson SA; Koleva RI; Cline JM; Marto JA; Myers MG; Carter-Su C
Mol Endocrinol; 2010 May; 24(5):1062-76. PubMed ID: 20304997
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.
Sanz A; Ungureanu D; Pekkala T; Ruijtenbeek R; Touw IP; Hilhorst R; Silvennoinen O
PLoS One; 2011 Apr; 6(4):e18522. PubMed ID: 21533163
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.
Bandaranayake RM; Ungureanu D; Shan Y; Shaw DE; Silvennoinen O; Hubbard SR
Nat Struct Mol Biol; 2012 Aug; 19(8):754-9. PubMed ID: 22820988
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
[TBL] [Abstract][Full Text] [Related]
11. Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2.
Funakoshi-Tago M; Pelletier S; Matsuda T; Parganas E; Ihle JN
EMBO J; 2006 Oct; 25(20):4763-72. PubMed ID: 17024180
[TBL] [Abstract][Full Text] [Related]
12. New insights into the structure and function of the pseudokinase domain in JAK2.
Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
[TBL] [Abstract][Full Text] [Related]
13. Determinants of growth hormone receptor down-regulation.
Deng L; He K; Wang X; Yang N; Thangavel C; Jiang J; Fuchs SY; Frank SJ
Mol Endocrinol; 2007 Jul; 21(7):1537-51. PubMed ID: 17488973
[TBL] [Abstract][Full Text] [Related]
14. A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation.
Zhao L; Dong H; Zhang CC; Kinch L; Osawa M; Iacovino M; Grishin NV; Kyba M; Huang LJ
J Biol Chem; 2009 Sep; 284(39):26988-98. PubMed ID: 19638629
[TBL] [Abstract][Full Text] [Related]
15. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
16. Activation of JAK2-V617F by components of heterodimeric cytokine receptors.
Pradhan A; Lambert QT; Griner LN; Reuther GW
J Biol Chem; 2010 May; 285(22):16651-63. PubMed ID: 20363735
[TBL] [Abstract][Full Text] [Related]
17. Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
Wan X; Ma Y; McClendon CL; Huang LJ; Huang N
PLoS Comput Biol; 2013 Apr; 9(4):e1003022. PubMed ID: 23592968
[TBL] [Abstract][Full Text] [Related]
18. Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.
Leroy E; Dusa A; Colau D; Motamedi A; Cahu X; Mouton C; Huang LJ; Shiau AK; Constantinescu SN
Biochem J; 2016 Jun; 473(11):1579-91. PubMed ID: 27029346
[TBL] [Abstract][Full Text] [Related]
19. On the regulation and activation of JAK2: a novel hypothetical model.
Lee TS
Mol Cancer Res; 2013 Aug; 11(8):811-4. PubMed ID: 23615525
[TBL] [Abstract][Full Text] [Related]
20. Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity.
Funakoshi-Tago M; Pelletier S; Moritake H; Parganas E; Ihle JN
Mol Cell Biol; 2008 Mar; 28(5):1792-801. PubMed ID: 18160720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
